Frühwein Markus, Schelling Jörg, Wahle Klaus, Beier Dietmar, Kwetkat Anja, Schwarz Tino F
Dr. Frühwein & Partner - Praxis für Allgemein-, Tropen- und Reisemedizin, München.
Hausärztliche Gemeinschaftspraxis Martinsried, München.
Dtsch Med Wochenschr. 2023 Apr;148(9):556-562. doi: 10.1055/a-2032-1368. Epub 2023 Mar 29.
Seasonal influenza causes a significant burden of disease in the German population and is associated with high societal costs. Persons aged 60 years and older are particularly at risk due to immunosenescence and chronic disease and account for a large proportion of influenza-associated hospitalizations and deaths. Adjuvanted, high-dose, recombinant and cell-based influenza vaccines have been developed to improve the effectiveness compared with conventional vaccines. Recent observational studies show better effectiveness of adjuvanted vaccine over conventional vaccines and similar effectiveness to the high-dose vaccine in older adults. Some countries have already considered the new evidence in their vaccination recommendations for the current or earlier seasons. The availability of the vaccines for older adults should also be ensured in Germany to guarantee a high level of vaccination protection.
季节性流感给德国民众带来了沉重的疾病负担，并产生了高昂的社会成本。60岁及以上的人群由于免疫衰老和慢性病，尤其面临风险，且在流感相关的住院和死亡病例中占很大比例。为提高与传统疫苗相比的有效性，已研发出佐剂流感疫苗、高剂量流感疫苗、重组流感疫苗和细胞培养流感疫苗。近期的观察性研究表明，在老年人中，佐剂疫苗比传统疫苗具有更好的有效性，且与高剂量疫苗的有效性相似。一些国家已在其针对当前或更早季节的疫苗接种建议中考虑了这一新证据。德国也应确保为老年人提供这些疫苗，以保证高水平的疫苗接种保护。
